Cross-talk between the thyroid and liver: A new target for nonalcoholic fatty liver disease treatment

被引:28
|
作者
Huang, Yue-Ye [1 ]
Gusdon, Aaron M. [3 ]
Qu, Shen [1 ,2 ]
机构
[1] Tongji Univ, Shanghai Peoples Hosp 10, Dept Endocrinol & Metab, Sch Med, Shanghai 200072, Peoples R China
[2] Nanjing Med Univ, Dept Endocrinol & Metab, Nanjing 210029, Jiangsu, Peoples R China
[3] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA
关键词
Thyroid hormone; Thyroid hormone receptor; Nonalcoholic fatty liver disease; Obesity; HORMONE RECEPTOR-BETA; HEPATIC INSULIN-RESISTANCE; BONE-MINERAL DENSITY; BROWN ADIPOSE-TISSUE; AGONIST GC-1; ALPHA-GENE; TR-BETA; METABOLIC SYNDROME; NUCLEAR RECEPTOR; BODY-WEIGHT;
D O I
10.3748/wjg.v19.i45.8238
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) has been recognized as the most common liver metabolic disease, and it is also a burgeoning health problem that affects one-third of adults and is associated with obesity and insulin resistance now. Thyroid hormone (TH) and its receptors play a fundamental role in lipid metabolism and lipid accumulation in the liver. It is found that thyroid receptor and its isoforms exhibit tissue-specific expression with a variety of functions. TR beta 1 is predominantly expressed in the brain and adipose tissue and TR beta 2 is the major isoform in the liver, kidney and fat. They have different functions and play important roles in lipid metabolism. Recently, there are many studies on the treatment of NAFLD with TH and its analogues. We review here that thyroid hormone and TR are a potential target for pharmacologic treatments. Lipid metabolism and lipid accumulation can be regulated and reversed by TH and its analogues. (C) 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码:8238 / 8246
页数:9
相关论文
共 50 条
  • [41] Liver transplantation for nonalcoholic fatty liver disease:New challenges and new opportunities
    Mina Shaker
    Adam Tabbaa
    Mazen Albeldawi
    Naim Alkhouri
    World Journal of Gastroenterology, 2014, (18) : 5320 - 5330
  • [42] Mechanisms of liver disease: cross-talk between the NF-κB and JNK pathways
    Papa, Salvatore
    Bubici, Concetta
    Zazzeroni, Francesca
    Franzoso, Guido
    BIOLOGICAL CHEMISTRY, 2009, 390 (10) : 965 - 976
  • [43] Liver transplantation for nonalcoholic fatty liver disease: New challenges and new opportunities
    Shaker, Mina
    Tabbaa, Adam
    Albeldawi, Mazen
    Alkhouri, Naim
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (18) : 5320 - 5330
  • [44] The TRIM family as a potential target for nonalcoholic fatty liver disease
    Liu, Yuanbin
    Chen, Mingkai
    HUMAN CELL, 2023, 36 (02) : 870 - 871
  • [45] Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation
    Carter, Danielle
    Dieterich, Douglas T.
    Chang, Charissa
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 213 - +
  • [46] The TRIM family as a potential target for nonalcoholic fatty liver disease
    Yuanbin Liu
    Mingkai Chen
    Human Cell, 2023, 36 : 870 - 871
  • [47] Pyruvate Dehydrogenase as a Therapeutic Target for Nonalcoholic Fatty Liver Disease
    Saed, Christina T.
    Dakhili, Seyed Amirhossein Tabatabaei
    Ussher, John R.
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2021, 4 (02) : 582 - 588
  • [48] Nonalcoholic Fatty Liver Disease and Liver Transplantation
    Tuan Pham
    Dick, Travis B.
    Charlton, Michael R.
    CLINICS IN LIVER DISEASE, 2016, 20 (02) : 403 - +
  • [49] Nonalcoholic fatty liver disease
    Alfie, ME
    Treem, WR
    PEDIATRIC ANNALS, 2006, 35 (04): : 290 - +
  • [50] Nonalcoholic fatty liver disease
    Clark, JM
    Brancati, FL
    Diehl, AM
    GASTROENTEROLOGY, 2002, 122 (06) : 1649 - 1657